Want to see DOCS full AI Analyst Report?
EarningsQ1 2027 Earnings Report
DOCS Q1 2027 EPS Results
Actual EPS$0.29
Consensus EPS$0.30
Beat/MissMissed by -$0.01
One Year Ago EPS$0.36
DOCS Q1 2027 Revenue Results
Actual Revenue$156.62M
Expected Revenue$151.77M
Beat/MissBeat by +$4.85M
YoY Revenue Growth+7.34%
Earnings Announcement Details
QuarterQ1 2027
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
DOCS Upcoming Earnings
Doximity's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q1 2027 Earnings Call Audio
DOCS Q1 2027 Earnings Call
0:00 / 0:00
Q1 2027 Earnings Slide Deck
No slide deck is available for this earnings event.
Q1 2027 Earnings Call Summary
Earnings Call Sentiment|Positive
The call combined strong financial and operational positives — revenue and adjusted EBITDA beats, raised full‑year guidance, robust cash balance, aggressive share repurchases, independent validation of Doximity Ask, rapid clinician adoption and meaningful enterprise wins — with managed near‑term tradeoffs driven by deliberate AI investment. Short‑term impacts include lower gross margin from compute spend, higher OpEx and a cautious Q2 growth comp, but management positioned these as intentional investments to capture a large long‑term AI opportunity while preserving high margins. Overall the positives (beat, guidance raise, product validation, adoption and balance sheet strength) outweigh the near‑term headwinds tied to investment cadence and timing of AI monetization.Company Guidance
Revenue Reacceleration and Guidance Raise
Q1 revenue of $157M, up 7% year‑over‑year and ~3% above the high end of guidance; full‑year guidance raised to $671M–$681M (midpoint ~5% YoY growth). Q2 revenue expected $170M–$171M (midpoint ~1% YoY) with AI revenue ramp expected in Q3.
Very Strong Profitability Metrics
Adjusted EBITDA of $75M in Q1 representing a 48% margin (beat vs guidance ~8%); full‑year adjusted EBITDA guidance $309M–$329M (midpoint ~47% margin). Non‑GAAP EPS $0.29; GAAP EPS $0.13.
Robust Cash Position and Share Repurchases
Ended Q1 with $688M in cash, cash equivalents and marketable securities, no debt; generated $40M free cash flow in Q1 and repurchased $92M of shares (approx. $400M remaining authorization).
Enterprise AI Traction and Independent Validation
Doximity Ask led U.S. models in the independent NOHARM study (4.8% clinical error rate vs. Anthropic Fable 5 at 13.6%) and achieved highest safety ratings, supporting enterprise trust and procurement.
Rapid Clinician Adoption of AI Tools
Quarterly active workflow prescribers grew >30% YoY to record highs with nearly 50% using AI tools in Q1; AI prompt volume rose >25% quarter‑over‑quarter; AI Scribe note‑taking users increased ~10x in July versus prior month.
Health System and Large Customer Momentum
165 signed health system AI clients, including Northwestern, Penn Medicine and University of Michigan; 127 pharma/hospital customers each generating >$500K TTM (up 7% YoY) and accounting for 83% of revenue. Top 20 NRR 112%; overall NRR 107% (TTM).
Early Commercial Success of AI Search
Launched AI search in late April; secured an initial cohort of customers across more than two dozen programs with management stating current unit economics are attractive ( >10x revenue per search vs cost) and majority of contracted AI search revenue expected to be recognized in Q3.
Differentiated Safety and Content Controls
Differentiators include an embedded, expert‑verified drug reference from the Pathway acquisition and ~12,000 physician PeerCheck editors continuously reviewing AI outputs — positioning Doximity for hospital enterprise adoption where liability and PHI concerns are critical.
DOCS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed